Abcam, ab183550, Anti-Cdk1 + Cdk2 (phospho T14) antibody [EPR17499]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal CDK1 phospho T14 antibody. Suitable for IP, Dot, WB, IHC-P and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR17499,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:Dot, IHC-P, WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cdk1 and Cdk2 also known as cyclin-dependent kinase 1 and cyclin-dependent kinase 2 are essential enzymes in the regulation of the cell cycle. These kinases play important roles in controlling the cell's transition through different stages of the cell cycle. Cdk1 has a molecular mass of about 34 kDa while Cdk2 weighs approximately 33 kDa. Both are expressed in various tissues with high expression levels found in proliferating cells. These kinases require binding to specific cyclins to activate their kinase activities which then phosphorylate target substrates involved in cell cycle progression.
Biological function summary
Cdks are pivotal in driving cell cycle phases collaborating with cyclins to regulate checkpoints at G1/S and G2/M transitions. Cdk1 primarily associates with cyclin B to facilitate the entry into mitosis whereas Cdk2 partners with cyclin E and cyclin A to advance the G1/S transition. Their activity is indispensable for proper cell cycle regulation and any misregulation can lead to uncontrolled cell proliferation. Importantly their involvement in complex formation ensures orderly progression and coordination across cell cycle stages.
Pathways
Cdk1 and Cdk2 integrate into the cell cycle regulation pathways and the DNA damage response pathways. In the cell cycle pathway Cdks are required for the orderly progression and checkpoints that ensure proper mitotic entry and DNA synthesis. Similarly in response to DNA damage these kinases work closely with proteins like p21 which can inhibit Cdk activity to halt cell cycle progression and facilitate DNA repair. By coordinating with related proteins like cyclins and p21 Cdk1 and Cdk2 help maintain genomic integrity through effective cell cycle control.
Cdk1 and Cdk2 have significant implications in cancer particularly as their overactivity often leads to tumorigenesis. Aberrations in Cdk-cyclin activity disrupt normal cell cycle control contributing to unchecked cell division seen in cancers. Moreover Cdk2 has connections to neurodegenerative diseases where its deregulation may contribute to neuronal cell death. These kinases relate to proteins such as p53 in cancer pathways and have become targets for pharmacological inhibition to restore controlled cell growth in cancer therapy.